Fluicell Capital Markets Day

Updtae 2023-05-23 All the talks from the Capital Markets Day are now available here: https://fluicell.com/capital-markets-day-2023/. You can also…

Read more
22 May 2023

“Fluicell is advancing in the right direction” interview with CEO Victoire Viannay

Our plan is to continue to advance in all our three business areas: research solutions, human in vitro…

Read more
19 May 2023

Closing the loop on type 1 diabetes – therpaeutic development whitepaper

Fluicell’s type 1 diabetes development program is aimed at creating patient-tailored artificial pancreatic islets capable of enabling glycemic…

Read more
16 May 2023

Fluicell publishes 2023 Q1 interim report

Today, May 12 2023, Fluicell publishes the Q1 interim report for the period January to March, 2023. The…

Read more
12 May 2023

90 students experience bioprinting at Fluicell

We at Fluicell are passionate about research and science and always want to take the opportunity to inspire…

Read more
08 May 2023

Capital Markets Day, May 22

We invite you to participate in our Capital Markets Day for a look into Fluicell’s development and future…

Read more
05 May 2023

Bioprinted liver model application note

The liver plays a central role during drug development because of its function in drug metabolization. Having an…

Read more
26 Apr 2023

Årsstämma 2023

Aktieägarna i Fluicell AB (publ), org. nr 556889-3282, (”Bolaget”) kallas härmed till årsstämma onsdagen den 17 maj 2023…

Read more
17 Apr 2023

Fluicell CEO Newsletter 01, 2023

We at Fluicell have had an exciting start to this year, with advances across all three business areas….

Read more
11 Apr 2023